India Pharma Outlook Team | Thursday, 05 March 2026
.png "India Proposes Biomanufacturing Working Group With Delaware")
India is stepping up its biotech game. Union Minister for Science and Technology Dr. Jitendra Singh has proposed a India–Delaware biomanufacturing working group aimed at turning discussions into tangible collaborations in research, manufacturing, and startups.
The announcement came during a meeting with a U.S. delegation led by Delaware Governor Matt Meyer at Seva Teerth, highlighting the growing state-level dimension of the India–US strategic partnership.
Dr. Jitendra emphasized that science, technology, and biotechnology remain a core pillar of India’s engagement with the United States. He pointed out India’s emergence as a global hub for biotechnology and pharmaceutical innovation, from research and development to large-scale, cost-efficient manufacturing. The Council of Scientific and Industrial Research (CSIR), with its 37 laboratories and over 7,500 scientists, anchors much of the nation’s industrial research and innovation efforts.
Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future
Delaware, with its thriving bio-science ecosystem and institutions like the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), presents a strategic partner. The collaboration could accelerate advanced biomanufacturing, AI-enabled processes, and rapid scale-up technologies. Dr. Singh noted that India’s manufacturing strengths combined with Delaware’s proximity to major U.S. pharmaceutical companies could help co-develop affordable biologics, biosimilars, and vaccines, strengthening global health supply chains.
Dr. Sridevi Khambhampaty — CEO, Shilpa Biologicals, while discussing evolving collaboration and advanced manufacturing models in India’s biopharma industry said, “We’ve kept a very flexible model… and as the biotech ecosystem has matured, companies are now excited to jump into innovation and novel products.”
The working group aims to foster joint biomanufacturing platforms, translational research, startup incubation, and workforce co-training. Focus areas include Good Manufacturing Practice (GMP) compliance, regulatory science, and quality systems. Regulatory alignment and resilient supply chains for biopharmaceutical inputs were also highlighted as key priorities. India’s Ministry of Science and Technology currently supports around 150 incubators, and the government has set up a Rs 1 trillion research, development, and innovation fund to catalyze private-sector investment and deep-tech growth.
Discussions with the Delaware delegation also covered clean energy, workforce development, and frameworks for startup incubation and corporate incorporation. Both sides agreed that a structured working group could move conversations into actionable programs, including joint research calls, startup exchanges, and institutional partnerships. This initiative signals a state-level approach to boosting India–US collaboration beyond national policies, enhancing innovation-led industrial growth.
Key Data and Insights
This proposed working group positions India as a leading player in biomanufacturing, fostering international collaborations while strengthening domestic innovation and industrial capacities. Both India and Delaware are now set to explore joint ventures that could reshape the biotech landscape, combining research excellence, manufacturing expertise, and startup dynamism.
